» Articles » PMID: 38857990

Patient-derived Organoid Biobank Identifies Epigenetic Dysregulation of Intestinal Epithelial MHC-I As a Novel Mechanism in Severe Crohn's Disease

Abstract

Objective: Epigenetic mechanisms, including DNA methylation (DNAm), have been proposed to play a key role in Crohn's disease (CD) pathogenesis. However, the specific cell types and pathways affected as well as their potential impact on disease phenotype and outcome remain unknown. We set out to investigate the role of intestinal epithelial DNAm in CD pathogenesis.

Design: We generated 312 intestinal epithelial organoids (IEOs) from mucosal biopsies of 168 patients with CD (n=72), UC (n=23) and healthy controls (n=73). We performed genome-wide molecular profiling including DNAm, bulk as well as single-cell RNA sequencing. Organoids were subjected to gene editing and the functional consequences of DNAm changes evaluated using an organoid-lymphocyte coculture and a nucleotide-binding oligomerisation domain, leucine-rich repeat and CARD domain containing 5 (NLRC5) dextran sulphate sodium (DSS) colitis knock-out mouse model.

Results: We identified highly stable, CD-associated loss of DNAm at major histocompatibility complex (MHC) class 1 loci including and cognate gene upregulation. Single-cell RNA sequencing of primary mucosal tissue and IEOs confirmed the role of NLRC5 as transcriptional transactivator in the intestinal epithelium. Increased mucosal MHC-I and NLRC5 expression in adult and paediatric patients with CD was validated in additional cohorts and the functional role of MHC-I highlighted by demonstrating a relative protection from DSS-mediated mucosal inflammation in NLRC5-deficient mice. MHC-I DNAm in IEOs showed a significant correlation with CD disease phenotype and outcomes. Application of machine learning approaches enabled the development of a disease prognostic epigenetic molecular signature.

Conclusions: Our study has identified epigenetically regulated intestinal epithelial MHC-I as a novel mechanism in CD pathogenesis.

Citing Articles

Novel therapeutic strategies and recent advances in gut microbiota synergy with nanotechnology for colorectal cancer treatment.

Han Q, Li J, Li Z, Aishajiang R, Yu D Mater Today Bio. 2025; 31:101601.

PMID: 40066079 PMC: 11891152. DOI: 10.1016/j.mtbio.2025.101601.


Tryptophan metabolites profile predict remission with dietary therapy in pediatric Crohn's disease.

Sigall Boneh R, van der Kruk N, Wine E, Verburgt C, de Meij T, Lowenberg M Therap Adv Gastroenterol. 2025; 18:17562848251323004.

PMID: 40012837 PMC: 11863242. DOI: 10.1177/17562848251323004.


New insights into the structure domain and function of NLR family CARD domain containing 5.

Zhu H, Xiao C, Chen J, Guo B, Wang W, Tang Z Cell Commun Signal. 2025; 23(1):42.

PMID: 39849460 PMC: 11755879. DOI: 10.1186/s12964-024-02012-y.

References
1.
Jung P, Sato T, Merlos-Suarez A, Barriga F, Iglesias M, Rossell D . Isolation and in vitro expansion of human colonic stem cells. Nat Med. 2011; 17(10):1225-7. DOI: 10.1038/nm.2470. View

2.
Ungaro R, Mehandru S, Allen P, Peyrin-Biroulet L, Colombel J . Ulcerative colitis. Lancet. 2016; 389(10080):1756-1770. PMC: 6487890. DOI: 10.1016/S0140-6736(16)32126-2. View

3.
Castro-Dopico T, Dennison T, Ferdinand J, Mathews R, Fleming A, Clift D . Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis. Immunity. 2019; 50(4):1099-1114.e10. PMC: 6477154. DOI: 10.1016/j.immuni.2019.02.006. View

4.
Elmentaite R, Kumasaka N, Roberts K, Fleming A, Dann E, King H . Cells of the human intestinal tract mapped across space and time. Nature. 2021; 597(7875):250-255. PMC: 8426186. DOI: 10.1038/s41586-021-03852-1. View

5.
Price M, Cotton A, Lam L, Farre P, Emberly E, Brown C . Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenetics Chromatin. 2013; 6(1):4. PMC: 3740789. DOI: 10.1186/1756-8935-6-4. View